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ABSTRACT
Introduction. In this edition, Szymanski et al. present the results of their retrospective study of the clinical differences between 
patients with meningococcal meningitis and pneumococcal cerebrospinal meningitis at the Regional Specialistic Hospital in 
Wroclaw, Poland. 
Clinical reflections. The authors found that compared to patients with N. meningitidis, patients with S. pneumoniae were older, 
more frequently had chronic comorbidities, and had higher rates of pneumonia, longer hospitalisations, and higher mortality. 
Patients with N. meningitidis had higher rates of haemorrhagic rash and DIC.
Clinical implications. These characteristics and outcomes reflect previous reports from Western Europe and the United States. 
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Bacterial meningitis has an incidence in developed countries of 
0.7–0.9 per 100,000, but remains as high as 40 per 100,000 in 
developing countries [1]. Previously described risk factors 
include an immonocompromised state such as age (infants 
and elderly), hyposplenia, HIV/AIDS, cancer, diabetes mel-
litus, alcoholism, and organ transplantation [2]. Before the 
advent of antibiotics, meningitis was typically fatal. But with 
the advent of pathogen-specific antimicrobials, vaccinations 
towards encapsalated bacteria, and corticosteroids, survival 
is now nearly 80% [3–5]. Although Europe, especially the 
Netherlands, has led the way in clinical meningitis research, 
the differing health systems across the continent may change 
the clinical characteristics and outcomes of meningitis. 
Szymanski et al. conducted a  retrospective study over 
a 20-year period at the J. Gromkowski Regional Specialistic 
Hospital in Wroclaw, Poland [6]. Their study reflected several 
previously reported characteristics regarding patients with S. 
pneumoniae and N. meningitidis. Pneumococcal meningitis 
patients were more likely to be older and to have chronic 
disease, to experience a longer delay in diagnosis, and to have 
lower levels of white blood cells in their CSF, higher rates of 
pneumonia, longer hospitalisations, and higher mortality. 
Meningococcal meningitis patients were far more likely to 
present with headache and vomiting, with over 60% having 
a haemorraghic rash, and around 30% developing DIC. No 
patients with menigococcal meningitis died during their 
study, whereas about 21% of the pneumococcal patients died. 
These are numbers that reflect Western European and USA 
experience. 
The clinical course of meningitis, including mortality, can 
vary geographically due to variations in bacterial serotypes, 
rates of vaccination, rates of immunocompromised states, 
access to acute healthcare and hospitals, and genetic suscepti-
bility. Most epidemiological work has been done in either 
Western Europe or North America or in developing countries 
of South America, Africa, and Asia. This is the first study to 
have investigated the differences between these diseases in 
the Polish population. This study shows that Polish patients 
at this hospital present with typical clinical findings, receive 
quick and appropriate treatment including corticosteroids 
(95%), and have similar mortality outcomes to those found 
in previous studies. 
References
1. Brouwer M, Beek Dv. Epidemiology of community-acquired bacte-
rial meningitis. Current Opinion in Infectious Diseases. 2018; 31(1): 
78–84, doi: 10.1097/qco.0000000000000417.
7www.journals.viamedica.pl/neurologia_neurochirurgia_polska
Jason L. Siegel, Cerebrospinal meningitis: a global disease with regional variability?
2. Adriani KS, Brouwer MC, van de. Risk factors for community-acquired 
bacterial meningitis in adults. Neth J Med. 2015; 73(2): 53–60.
3. Buchholz G, Koedel U, Pfister HW, et al. Dramatic reduction of mor-
tality in pneumococcal meningitis. Crit Care. 2016; 20(1): 312, doi: 
10.1186/s13054-016-1498-8, indexed in Pubmed: 27716447.
4. Brouwer MC, McIntyre P, Prasad K, et al. Corticosteroids for acute bacte-
rial meningitis. Cochrane Database Syst Rev. 2010(9): CD004405, doi: 
10.1002/14651858.CD004405.pub3, indexed in Pubmed: 20824838.
5. Brouwer MC, Heckenberg SGB, de Gans J, et al. Nationwide imple-
mentation of adjunctive dexamethasone therapy for pneumococcal 
meningitis. Neurology. 2010; 75(17): 1533–1539, doi: 10.1212/
WNL.0b013e3181f96297, indexed in Pubmed: 20881273.
6. Szymański W, Simon KA, Rorat M. Differences in the courses of me-
ningococcal and pneumococcal cerebrospinal meningitis. Neurol Neu-
rochir Pol. 2020; 54(1): 39–46, doi: 10.5603/PJNNS.a2020.0002, 
indexed in Pubmed: 31956973.
